XAP044 is primarily used in research settings to study its effects on the central nervous system, particularly in the context of neurological disorders. It acts as a selective antagonist of metabotropic glutamate receptor 7 (mGlu7), making it a valuable tool for understanding the role of this receptor in conditions such as anxiety, depression, and epilepsy. Researchers utilize it to explore potential therapeutic applications, as modulating mGlu7 activity may offer new avenues for treating these disorders. Its application is largely confined to preclinical studies, where it helps to elucidate the underlying mechanisms of glutamate signaling and its impact on brain function.